Tom Cupedo

Tom Cupedo

Auto-generated profile, based on publicly available information

Tom Cupedo

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2008 in Nature Immunology
Verified
Journal Article
Closed access
TCTom Cupedo
Tom Cupedo
NCNatasha K Crellin
Natasha K Crellin
NPNatalie Papazian
Natalie Papazian
ERElwin J Rombouts
Elwin J Rombouts
KWKees Weijer
Kees Weijer
HSHergen Spits
Hergen Spits

20 May 2021 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
MJMadelon M. E. de Jong
Madelon M. E. de Jong
ZKZoltan Kellermayer
Zoltan Kellermayer
NPNatalie Papazian
Natalie Papazian
STSabrin Tahri
Sabrin Tahri
DBDavine Hofste Op Bruinink
Davine Hofste Op Bruinink
TCTom Cupedo
Tom Cupedo

21 September 2015 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
PAPatricia Aparicio-Domingo
Patricia Aparicio-Domingo
MRMonica Romera-Hernandez
Monica Romera-Hernandez
JKJulien J. Karrich
Julien J. Karrich
FCFerry Cornelissen
Ferry Cornelissen
NPNatalie Papazian
Natalie Papazian
TCTom Cupedo
Tom Cupedo
Disruption of the intestinal epithelial barrier allows bacterial translocation and predisposes to destructive inflammation. To ensure proper barrier composition, crypt-residing stem cells continuously proliferate and replenish all intestinal epithelial cells within days. As a consequence of this high mitotic activity, mucosal surfaces are frequently targeted by anticancer therapies, leading to dose-limiting side effects. The cellular mechanisms that control tissue protection and mucosal healing in response to intestinal damage remain poorly understood. Type 3 innate lymphoid cells (ILC3s) are regulators of homeostasis and tissue responses to infection at mucosal surfaces. We now demonstrate that ILC3s are required for epithelial activation and proliferation in response to small intestinal tissue damage induced by the chemotherapeutic agent methotrexate. Multiple subsets of ILC3s are activated after intestinal tissue damage, and in the absence of ILC3s, epithelial activation is lost, correlating with increased pathology and severe damage to the intestinal crypts. Using ILC3-deficient Lgr5 reporter mice, we show that maintenance of intestinal stem cells after damage is severely impaired in the absence of ILC3s or the ILC3 signature cytokine IL-22. These data unveil a novel function of ILC3s in limiting tissue damage by preserving tissue-specific stem cells.

1 January 2012 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
KHKerim Hoorweg
Kerim Hoorweg
CPCharlotte P. Peters
Charlotte P. Peters
FCFerry Cornelissen
Ferry Cornelissen
PAPatricia Aparicio-Domingo
Patricia Aparicio-Domingo
NPNatalie Papazian
Natalie Papazian
TCTom Cupedo
Tom Cupedo
Human RORC+ lymphoid tissue inducer cells are part of a rapidly expanding family of innate lymphoid cells (ILC) that participate in innate and adaptive immune responses as well as in lymphoid tissue (re) modeling. The assessment of a potential role for innate lymphocyte-derived cytokines in human homeostasis and disease is hampered by a poor characterization of RORC+ innate cell subsets and a lack of knowledge on the distribution of these cells in adults. Here we show that functionally distinct subsets of human RORC+ innate lymphoid cells are enriched for secretion of IL-17a or IL-22. Both subsets have an activated phenotype and can be distinguished based on the presence or absence of the natural cytotoxicity receptor NKp44. NKp44+ IL-22 producing cells are present in tonsils while NKp44− IL-17a producing cells are present in fetal developing lymph nodes. Development of human intestinal NKp44+ ILC is a programmed event that is independent of bacterial colonization and these cells colonize the fetal intestine during the first trimester. In the adult intestine, NKp44+ ILC are the main ILC subset producing IL-22. NKp44− ILC remain present throughout adulthood in peripheral non-inflamed lymph nodes as resting, non-cytokine producing cells. However, upon stimulation lymph node ILC can swiftly initiate cytokine transcription suggesting that secondary human lymphoid organs may function as a reservoir for innate lymphoid cells capable of participating in inflammatory responses.

1 April 2009 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
ÉVÉric Vivier
Éric Vivier
HSHergen Spits
Hergen Spits
TCTom Cupedo
Tom Cupedo

1 July 2006 in Blood
Verified
Journal Article
Closed access
PDF file
NLNicolas Legrand
Nicolas Legrand
TCTom Cupedo
Tom Cupedo
ALAnja U. van Lent
Anja U. van Lent
MEMenno J. Ebeli
Menno J. Ebeli
KWKees Weijer
Kees Weijer
HSHergen Spits
Hergen Spits
Efficient and quick reconstitution of T-cell compartments in lymphopenic patients is of great importance to prevent opportunistic infections, but remains difficult to achieve. Human T-cell proliferation in a T-cell-receptor (TCR)-independent manner is possible in vitro with superagonist anti-CD28 antibodies, and such molecules are therefore promising therapeutic tools. Here, we investigated the in vivo effects of superagonist anti-CD28 treatment on human developing and mature T cells, in the recently developed model of “human immune system” BALB/c Rag2-/-γc-/- mice. Our results show that superagonist anti-CD28 treatment transiently induces a 7-fold increase in thymocyte numbers and up to 18-fold accumulation of mature thymocytes. The increased thymic production lead to transient accumulation of mature T cells in the periphery at the peak of treatment effect (day 6). In addition, long-term peripheral T-cell depletion was induced. Furthermore, the concomitant selective expansion and accumulation of suppressive CD4+CD25+FoxP3+ T cells was induced in a transient manner. Superagonist anti-CD28 therapy could therefore be of clinical interest in humans, both for beneficial effect on thymic T-cell production as well as regulatory T-cell accumulation. (Blood. 2006;108:238-245)